MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$104K
Net Income
-$9,238K
Net Profit Margin
-8882.69%
EPS
-$0.14
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Royalty revenues
104
41
243
120
Research and development
5,915
6,765
5,075
8,197
Selling, general and administrative
3,804
6,126
2,995
3,897
Total operating expenses
9,719
12,891
8,070
12,094
Loss from operations
-9,615
-12,850
-7,827
-11,974
Interest income
382
506
612
716
Other income (expense), net
1
-1
-1
0
Total other income (expense), net
383
505
611
716
Net loss
-9,232
-12,345
-7,216
-11,258
Preferred stock dividend payable on series a convertible preferred stock
6
6
7
6
Net loss attributable to common stockholders
-9,238
-12,351
-7,223
-11,264
Basic EPS
-0.14
-0.18
-0.107
-0.17
Diluted EPS
-0.14
-0.18
-0.107
-0.17
Basic Average Shares
68,397,000
68,350,000
67,435,000
66,879,000
Diluted Average Shares
68,397,000
68,350,000
67,435,000
66,879,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
attributable to common...
-$9,238K
(33.77%↑ Y/Y)
Interest income
$382K
(-54.25%↓ Y/Y)
Other income
(expense), net
$1K
(200.00%↑ Y/Y)
Net loss
-$9,232K
(33.79%↑ Y/Y)
Preferred stock dividend
payable on series a...
$6K
(0.00%↑ Y/Y)
Total other income
(expense), net
$383K
(-54.08%↓ Y/Y)
Loss from operations
-$9,615K
(34.93%↑ Y/Y)
Royalty revenues
$104K
(-14.05%↓ Y/Y)
Total operating
expenses
$9,719K
(-34.76%↓ Y/Y)
Research and development
$5,915K
(-48.92%↓ Y/Y)
Selling, general and
administrative
$3,804K
(14.65%↑ Y/Y)
Buy us a coffee
Cardiff Oncology, Inc. (CRDF)
Cardiff Oncology, Inc. (CRDF)